HOT NEWS
European Commission Issues Positive Decision for Approval of Seroquel XR » AstraZeneca announced that the European Commission (EC) has issued a positive decision for the appro...
Data from Mipomersen Phase 3 Trial in heFH Patients Presented at ESC » Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) announced that data from t...
Global market launch of Daxas® (Roflumilast) kicks off in Germany » Stefan Brinkmann, Managing Director of Nycomed GmbH, kicked off the German market launch of Daxas® ...
A new era for patients with atrial fibrillation - Dabigatran etexilate at the fo... » The European Society of Cardiology (ESC) issued revised practice guidelines for the management of at...
Genetic substudy shows fewer major cardiovascular events with ticagrelor (BRILIN... » A new genetic substudy of PLATO (A Study of PLATelet Inhibition and Patient Outcomes) showed that th...
Shire Announces European Approval of VPRIV® (velaglucerase alfa) » Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today...
Bristol-Myers Squibb and Pfizer Inc Evaluate Unmet Need in Patients with Atrial ... » Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) report that preliminary results from...
GSK European Commission amends licence for Cervarix® » GlaxoSmithKline (GSK) confirmed that the European Commission has granted Marketing Authorisation to ...
Amgen Announces Top-Line Results of Phase 3 Head and Neck Cancer Trial » Amgen (Nasdaq: AMGN) announced top-line results from a randomized Phase 3 trial evaluating Vectibix(...
Pfizer Reports Second-Quarter 2010 Results » Pfizer Inc. (NYSE: PFE) has reported financial results for second-quarter 2010. Since the acquisitio...
Sanofi-aventis
sanofi-aventisSanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT : SAN) and in New York (NYSE : SNY). For further information, please visit www.sanofi-aventis.com.

Sanofi-aventis RSS Channel
Title Filter     Display # 
# Article Title Hits
1 Sanofi-aventis Initiates 10,000 Patient Study with Multaq® in Permanent Atrial Fibrillation 1375
2 Sanofi-aventis and CureDM Sign Exclusive Worldwide License Agreement on Novel Regenerative Compound to Treat Diabetes 1008
3 AgaMatrix and sanofi-aventis Enter Global Diabetes Partnership 1223
4 Sanofi Pasteur's A(H1N1) Vaccine HUMENZA®* Recommended by European Medicines Agency 1381
5 My child matters Supports Seven New Childhood Cancer Care Projects 1082
6 Multaq® Approved in the European Union for patients with atrial fibrillation 1350
7 Panenza® and Humenza® Influenza A(H1N1) Vaccines Demonstrate Robust Immune Response After One Dose 3588
8 Multaq® (dronedarone) Recommended for Approval in the European Union 1669
9 Sanofi Pasteur and Butantan Institute to Provide A(H1N1) Vaccine to Brazilian Government 1358
10 5-year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus® Compared to NPH 1323
11 Sanofi-aventis to strengthen Insulin Production Capacities 855
12 Update on Clopidogrel centralized applications in the European Union 766
13 Sanofi-aventis introduces sanofi-aventis TV "A window on our company" 790
14 Sanofi-aventis builds a New Vaccine Manufacturing Facility in France with an investment of 350 million euros 1159
15 Sanofi-aventis invests €100 million in new facility in Mexico 1087
16 INTANZA®/IDflu®, first intradermal influenza vaccine, approved in the European Union 1403
17 New England Journal of Medicine publishes results from the landmark ATHENA trial 1416
18 European Commission Clears Acquisition of Zentiva NV by sanofi-aventis 914
19 Sanofi-aventis and Novozymes announce a development and commercialization collaboration 848
 
Bookmark and Share